Focused On-demand Library for Serine/threonine-protein kinase LMTK3

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q96Q04

UPID:
LMTK3_HUMAN

ALTERNATIVE NAMES:
Lemur tyrosine kinase 3

ALTERNATIVE UPACC:
Q96Q04; Q4G0U1

BACKGROUND:
LMTK3, known for its alternative name Lemur tyrosine kinase 3, is crucial in phosphorylating ESR1 and protecting it against degradation. This kinase is integral in the PKC-AKT-FOXO3 pathway, influencing ESR1 transcription and playing a role in the trafficking of NMDAR in neurons, which is essential for synaptic function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of LMTK3 offers a promising avenue for developing novel therapeutic interventions. Its regulatory effect on ESR1 and involvement in neuronal receptor dynamics make it a compelling target for addressing disorders linked to hormone receptor activity and neuronal communication.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8270 of 8789